Strides Arcolab, a pharmaceutical company manufacturing IP-led niche products, today announced the launch of generic drug Sofosbuvir in India under the brand name 'Virso'.

In September 2014, Strides entered into a licensing agreement with Gilead Sciences, Inc to bring Hepatitis C cure to 91 developing countries. The product will be available to Indian Patients shortly.

Mohan Kumar, CEO, pharma said, ''We are pleased to announce this launch in partnership with Gilead Sciences, which is a big leap in our commitment towards bringing critical healthcare at affordable cost.''

Shares of the company declined Rs 14.4, or 1.35%, to trade at Rs 1,049.30. The total volume of shares traded was 65,707 at the BSE (1.51 p.m., Friday).